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CASE REPORT
A 63-year-old female was admitted to our hospital with a tender abdominal wall mass about 15 cm in diameter,
which she had for 1 month. About 1 week earlier, the patient had also perceived a mass in the neck area.
Computed tomography revealed huge thyroid and periumbilical masses. The thyroid hormone levels were
consistent with a hyperthyroid state. Pathological examination of the thyroid mass was compatible with anaplastic
thyroid carcinoma (ATC) and the abdominal cutaneous mass was shown to be metastatic ATC. Despite palliative
radiotherapy and chemotherapy, the patient died of respiratory failure on her 63rd day of hospitalization. This case
demonstrates that abdominal cutaneous metastasis and hyperthyroidism can occur as initial manifestations of
ATC. To our knowledge, this is the first reported case. (Korean J Intern Med 2010;25:450-453)
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INTRODUCTION
Anaplastic thyroid carcinoma (ATC) is one of the most
aggressive endocrine tumors and has a poor prognosis
with a median survival of 4 to 12 months from the time of
diagnosis [1,2]. Fortunately, it accounts for only 1 to 2% of
all thyroid cancer [3]. The mean age at diagnosis is 55 to
65 years [1,2]. Systemic metastases occur in up to 75% of
patients during their illness, most commonly in the lungs
in up to 80% of cases, followed by bone in 6-15% and the
brain in 5-13% [4]. Skin metastases from thyroid
carcinoma are extremely rare and usually occur in the
setting of disseminated neoplastic disease [5].
Furthermore, primary thyroid malignancies typically do
not interfere with thyroid function and the presentation of
ATC with hyperthyroidism is extremely rare. Several case
reports on subjects with ATC and hyperthyroidism have
been published [6-15]. Here, we describe a rare case that
presented with abdominal cutaneous metastasis from
ATC, concurrent with the development of hyperthyroidism.
CASE REPORT
A 63-year-old female was admitted to our hospital for
the evaluation of a huge abdominal mass. One month
earlier, when the patient first perceived the abdominal
mass, it measured about 2 cm. Recently, a neck mass also
increased rapidly in size, with accompanying dysphagia,
shortness of breath, and hoarseness. She had no history of
goiter. On physical examination, she had a resting
tachycardia with a pulse rate of 100-110 per minute. The
abdominal mass was about 15 cm in diameter (Fig. 1A). A
huge, firm neck mass occupied both lobes of the thyroid,
with palpable lymph nodes on the left (Fig. 1B). She also
had a 3-cm skin nodule on her right thigh that was hard
and non-tender (Fig. 1C). Computed tomography (CT)
revealed huge thyroid (Fig. 2A) and periumbilical (Fig.
2B) masses, infiltrating adjacent tissues. The abdominal
mass was based primarily in the subcutaneous fat layer. A
pulmonary mass, suggestive of metastasis, was also
detected by CT. There was no definite evidence of boneLim KH,et al. Anaplastic thyroid carcinoma with cutaneous metastasis and hyperthyroidism   451
metastasis on a bone scan. The initial thyroid function
tests were consistent with a hyperthyroid state: thyroid
stimulating hormone (TSH) < 0.11 mU/L (normal range,
0.4 to 4.1); free T4 (fT4) 3.34 ng/dL (normal range, 0.70
to 1.80); thyroglobulin 171.8 ng/mL (normal range, 0 to
40); and thyroglobulin antibody 85 U/mL (normal range,
0 to 100 U/mL). Anti-thyroglobulin antibody, anti-thyroid
peroxidase antibody, and serum calcitonin were all
normal.
Fine needle aspiration of the thyroid mass revealed
many large, pleomorphic, epithelioid cells forming loose
clusters and was compatible with anaplastic carcinoma of
the thyroid (Fig. 3A). The histological features of the
excised periumbilical mass were similar to those in the
thyroid and the lesion was diagnosed as metastatic ACT
(Fig. 3B). Immunohistochemical staining of the
abdominal wall mass was positive for cytokeratin-7 and
negative for cytokeratin-20, thyroid transcription factor-1,
and thyroglobulin.
After the diagnosis of ATC was made, palliative
radiotherapy to the neck area was initiated on the 15th day
of hospitalization, to relieve local symptoms associated with
the thyroid mass. Although this patient had asymptom-
atic hyperthyroidism, she was given propylthiouracil
preemptively because of the possibility of radiotherapy-
induced thyrotoxicosis. During radiotherapy, the thyroid
Figure 1. A periumbilical mass about 15 cm in diameter (A), thyroid mass (B), and another skin lesion on the right thigh (C) were
detected at the initial physical examination.
Figure 2. Computed tomography revealed a huge thyroid mass (A) and a cutaneous mass in the umbilical area (B).
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function tests were repeated on the 24th day and the fT4
and TSH levels were 3.09 ng/dL and < 0.05 mU/L,
respectively. However, she had no thyrotoxic symptoms
except tachycardia. The dyspnea was improved after the
completion of radiotherapy (35 Gy/14 fractions) and
systemic chemotherapy (paclitaxel) was administered on
the 36th day. However, the tumor had an aggressive
course despite chemotherapy. The patient developed vocal
cord paralysis with severe airway compromise and died of
respiratory distress on her 63rd day of hospitalization.
DISCUSSION
Anaplastic thyroid carcinoma is one of the most lethal
solid tumors in humans. It aggressively invades adjacent
tissues and frequently metastasizes to distant organs via
the bloodstream. Distant metastases of ATC are usually
localized in the lung, bone, and brain [4]. Cutaneous
metastasis of thyroid cancer is very rare. The frequency of
skin metastasis varies with the histological type of thyroid
cancer. Dahl et al. [5] reviewed the English literature from
1964 onwards and found 43 cases of thyroid carcinoma
with skin metastases. They found that papillary carcinoma
was the most common thyroid cancer to result in skin
metastases, representing 41% of the cases, followed by
follicular carcinoma at 28%, with anaplastic carcinoma
and medullary carcinoma each constituting 15% of the
cases. By contrast, Koller et al. [16] reported that follicular
carcinoma has a greater preponderance for cutaneous
metastases than papillary carcinoma. Common cutaneous
metastatic sites for the thyroid carcinoma are the scalp
and neck [17,18]. However, cutaneous metastasis from
ATC as the initial presentation is extremely rare and
abdominal wall metastasis of ATC has not been reported.
A clinical presentation with hyperthyroidism is also rare
in ATC. Sekiguchi et al. [19] studied the biological
characteristics and chemosensitivity profiles in four
human anaplastic thyroid carcinoma cell lines and found
that all of four cell lines lost their differentiated function
and were unable to synthesize thyroid hormone. Consequ-
ently, primary thyroid cancers typically do not interfere
with thyroid function. The proposed mechanism for
thyrotoxicosis is invasion and destruction of the normal
thyroid parenchyma by the tumor, resulting in an
excessive release of pre-formed thyroid hormone into the
circulation. As this clinical presentation is analogous to
various forms of thyroiditis, Rosen et al. [20] called this
condition ‘malignant pseudothyroiditis’.  Subsequently, a
few case reports of ATC patients with symptomatic or
asymptomatic hyperthyroidism have been published [6-
15]. Although the thyroid function tests revealed overt
hyperthyroidism, our patient had no definite symptoms or
signs of thyrotoxicosis.
Figure 3. (A) Fine needle aspiration of the thyroid mass. The tumor is present as loose clusters or single cells and is composed of
epithelioid cells with pleomorphic nuclei (Papanicolaou, × 400). (B) Excisional biopsy specimen from the periumbilical area. The
tumor is composed of pleomorphic, epithelioid, and spindle cells with frequent mitotic figures (H&E, × 400).
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Survival after the diagnosis of ATC is extremely poor.
Since more than half of ATC patients have metastatic
disease at presentation, the importance of chemotherapy
in the management of ATC cannot be understated.
However, the outcomes of chemotherapy have been very
disappointing. Although doxorubicin is the drug used
most commonly, it has a response rate of less than 22%
and plays limited roles in the treatment of ATC [21]. In
one phase II clinical study, paclitaxel showed promising
results and had a 53% response rate [22]. However, this
potential role of paclitaxel needs to be evaluated further,
and our patient did not benefit from paclitaxel chemoth-
erapy.
In conclusion, this case demonstrates that an abdominal
cutaneous metastatic mass and hyperthyroidism can occur
as manifestations of ATC. To our knowledge, this is the first
reported case of ATC initially presenting with cutaneous
metastasis in the abdominal wall, concurrent with
hyperthyroidism. Further efforts to improve the treatment
results for ATC patients are needed.
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